Study Highlights Hurdles to U.S. Uptake of Inflectra
A new study (abstract attached) presented at the European Union League Against Rheumatism (EULAR) Conference highlights one of the main hurdles to...
246 Views
U.S. Remsima Expectations Too Optimistic
USFDA approved Celltrion’s Remsima, a biosimilar for JNJ’s Remicade, for use in treating rheumatoid arthritis, ulcerative colitis, Crohn’s, and...
311 Views
The Risks of High Expectations for Biosimilars
Celltrion trades at a premium valuation (35x 2016 estimated earnings) based on high expectations for its biosimilar (copycats of biotech) products....
334 Views